Page last updated: 2024-09-05

lenalidomide and arsenic

lenalidomide has been researched along with arsenic in 12 studies

Compound Research Comparison

Studies
(lenalidomide)
Trials
(lenalidomide)
Recent Studies (post-2010)
(lenalidomide)
Studies
(arsenic)
Trials
(arsenic)
Recent Studies (post-2010) (arsenic)
3,5327252,85027,80628013,049

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (83.33)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gibson, AD; Klem, J; Price, N; Reddy, GK1
Murakami, H1
Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R1
Hess, U1
Hussein, MA; Kalmadi, SR1
Takatoku, M1
Berenson, JR; Yellin, O1
Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT1
Gotlib, J; Greenberg, PL1
Gotlib, J; Oh, ST1
Aguayo, A; Armillas-Canseco, FM; Martínez-Baños, D1
Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E1

Reviews

9 review(s) available for lenalidomide and arsenic

ArticleYear
[New strategy for the treatment of multiple myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:12

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning

2005
New treatments for multiple myeloma.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:14

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide

2005
[The plasma cell myeloma--molecular pathogenesis and target therapies].
    Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors

2006
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Acta haematologica, 2006, Volume: 116, Issue:1

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide

2006
[Molecular targeting therapy for multiple myeloma].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A

2007
New drugs in multiple myeloma.
    Current opinion in supportive and palliative care, 2008, Volume: 2, Issue:3

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide

2008
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
    Thrombosis research, 2009, Volume: 123, Issue:5

    Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism

2009
Novel biospecific agents for the treatment of myelodysplastic syndromes.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2003, Volume: 1, Issue:4

    Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide

2003
Antiangiogenesis in myelodysplastic syndrome.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Thalidomide

2011

Other Studies

3 other study(ies) available for lenalidomide and arsenic

ArticleYear
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
    Clinical lymphoma, 2004, Volume: 4, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase

2004
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
    Current hematologic malignancy reports, 2008, Volume: 3, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide

2008
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14

    Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid

2017